X

Trial Profile

Actos Now for Prevention of Diabetes (ACT NOW)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pioglitazone (Primary)
Indications Glucose intolerance; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms ACT-NOW

Most Recent Events

11 Jun 2019 Results (n=441) assessing long-term effect of pioglitazone metabolic insulin clearance, presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
16 Sep 2016 Results assessing the effect of pioglitazone on Fibroblast Growth Factor-21 (FGF-21), presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association (n = 531).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com